复原通络方治疗糖尿病下肢血管病变支架植入再狭窄的临床观察
Clinical observation of Fuyuan Tongluo Formula in treatment of stent implantation and restenosis of diabetic lower limb vascular disease
- 上海中医药大学学报 2022年36卷第S1期 页码：40-44
- 作者机构：
1.上海中医药大学附属曙光医院血管外科（上海 201203）
- 作者简介：
杜玉青，女，在读博士生，主要从事中医外科治疗周围血管疾病的临床研究
柳国斌，主任医师，博士生导师；E-mail：drliuguobin@163.com
王宏飞，副主任医师；E-mail：w15801738507@126.com
- 基金信息：国家科学自然基金资助项目(81774310;81804096)
DOI：10.16306/j.1008-861x.2022.S1.010
中图分类号：
扫 描 看 全 文
杜玉青,柳国斌,王宏飞等.复原通络方治疗糖尿病下肢血管病变支架植入再狭窄的临床观察[J].上海中医药大学学报,2022,36(S1):40-44.
DU Yuqing,LIU Guobin,WANG Hongfei,et al.Clinical observation of Fuyuan Tongluo Formula in treatment of stent implantation and restenosis of diabetic lower limb vascular disease[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(S1):40-44.
杜玉青,柳国斌,王宏飞等.复原通络方治疗糖尿病下肢血管病变支架植入再狭窄的临床观察[J].上海中医药大学学报,2022,36(S1):40-44. DOI： 10.16306/j.1008-861x.2022.S1.010.
DU Yuqing,LIU Guobin,WANG Hongfei,et al.Clinical observation of Fuyuan Tongluo Formula in treatment of stent implantation and restenosis of diabetic lower limb vascular disease[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(S1):40-44. DOI： 10.16306/j.1008-861x.2022.S1.010.
摘要
目的,2,观察复原通络方治疗糖尿病下肢血管病变支架植入再狭窄的临床疗效。,方法,2,纳入糖尿病下肢血管病变支架植入再狭窄患者60例，随机分为中药组和对照组，每组各30例。两组均给予降糖、降压等西医常规治疗，在此基础上，中药组给予复原通络方，治疗6个疗程（4周为l个疗程）。比较两组患者临床总有效率、6 min步行和跛行距离、下肢踝肱指数（ABI）、经皮氧分压（TcPO,2,）、下肢动脉内径及安全性指标。,结果,2,①治疗6个月后，中药组总有效率90.0%，对照组总有效率80.0%，中药组的疗效优于对照组（,P,<,0.05）。②术后3个月、6个月中药组6 min步行距离显著长于对照组（,P,<,0.05）；术后6个月中药组6 min跛行距离显著长于对照组（,P,<,0.05）。③中药组静息ABI、TcPO,2,较对照组明显增加（,P,<,0.05）。④术后3个月、6个月，中药组患者股动脉、腘动脉、胫后动脉内径增宽优于照组（,P,<,0.05）。,结论,2,复原通络方能够改善糖尿病下肢血管病变支架植入再狭窄的临床症状，促进下肢血运重建，延缓再狭窄的发生。
Abstract
Objective： To explore the clinical efficacy of Fuyuan Tongluo Formula in the treatment of stent implantation and restenosis of diabetic lower limb vascular disease.,Methods,2,Sixty patients with stent implantation and restenosis of diabetic lower limb vascular disease were randomly divided into traditional Chinese medicine group and control group， 30 cases in each group. Both groups were treated with routine western medicine such as hypoglycemic and anti-hypertensive drugs. On this basis， the traditional Chinese medicine group was treated with Fuyuan Tongluo Formula for 6 treatment courses （4 weeks as one treatment course）. The total clinical effective rate， 6-minute walking and claudication distance， ABI， TcPO,2,， lower extremity artery diameter and safety indexes were compared between the two groups.,Results,2,①After treatment for 6 months， the total effective rate of the traditional Chinese medicine group was 90.0%， and that of the control group was 80.0%. The efficacy of the traditional Chinese medicine group was better than that of the control group （,P,<,0.05）. ②Three and six months after operation， the 6-minute walking distance in the traditional Chinese medicine group was significantly longer than that in the control group （,P,<,0.05）. Six months after operation， the 6-minute claudication distance in the traditional Chinese medicine group was significantly longer than that in the control group （,P,<,0.05）. ③The resting ABI and TcPO,2, in the traditional Chinese medicine group were significantly higher than those in the control group （,P,<,0.05）. ④Three and six months after operation， the diameters of femoral artery， popliteal artery and posterior tibial artery in the traditional Chinese medicine group were wider than those in the control group （,P,<,0.05）.,Conclusion,2,Fuyuan Tongluo Formula can improve the clinical symptoms of stent implantation and restenosis of diabetic lower limb vascular disease， promote the revascularization of lower extremities， and delay the occurrence of restenosis.
关键词
复原通络方糖尿病下肢血管病变支架植入再狭窄临床疗效
Keywords
Fuyuan Tongluo Formuladiabetic lower limb vascular diseasestent implantationrestenosisclinical efficacy
references
WANG K， LI Y， GAO F， Gong H， Li X， Ren X. Efficacy and Safety of TurboHawk Plaque Rotation Combined With Drug-coated Balloon in Treating Diabetic Patients With Lower Extremity Arterial Disease［J］. Clin Appl Thromb Hemost， 2020， 26： 1076029620915979.
FOWKES F G， RUDAN D， RUDAN I， et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010： a systematic review and analysis［J］. Lancet， 2013， 382（9901）： 1329-1340.
BOYKO E J， SEELIG A D， AHRONI J H. Limb- and person-level risk factors for lower-limb amputation in the prospective Seattle diabetic foot study［J］. Diabetes Care， 2018， 41（4）：891-898.
MOHAMMEDI K， WOODWARD M， Hirakawa Y， et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes： results from the ADVANCE-ON study［J］. Cardiovasc Diabetol， 2016， 15（1）： 129.
NATIVEL M， POTIER L， ALEXANDRE L， et al. Lower extremity arterial disease in patients with diabetes： a contemporary narrative review［J］. Cardiovasc Diabetol， 2018， 17（1）： 138.
ZENG W P， ZHANG R， LI R， et al. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent［J］. PloS One， 2017， 12（1）： e0170964.
YU J S， PARK K M， JEON Y S， et al. Midterm Outcome of Femoral Artery Stenting and Factors Affecting Patency［J］. Vasc Specialist Int， 2015， 31（4）： 115-119.
WERK M， ALBRECHT T， MEYER D R， et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty evidence from the randomized PACIFIER trial［J］. Circ Cardiovasc Interv， 2012， 5（6）： 831-840.
李雪松，刘汉庆. 奚九一“因邪致瘀，祛邪为先”学术思想浅析［J］. 湖北中医杂志，2013， 35（12）： 30.
中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）［J］. 国际内分泌代谢杂志，2021， 41（5）： 482-548.
李曰庆，何清湖. 中医外科学［M］. 北京：中国中医药出版社，2012.
周仲瑛. 中医内科学［M］. 北京：中国中医药出版，2003．
郑筱萸. 中药新药临床研究指导原则［M］. 北京：中国医药科技出版社，2002.
贾梦潇，李强，何洪波，等. 2型糖尿病患者下肢血管病变介入治疗远期再狭窄及影响因素分析［J］. 第三军医大学学报，2020， 42（2）： 162-167.
ZHANG X， RAN X， XU Z， et al. Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk： a prospective， multicenter， cross-sectional study［J］. J Diabetes Complications， 2018， 32（2）： 150-156.
STEG P G， BHATT D L， WILSON P W， et al. One-year cardiovascular event rates in outpatients with atherothrombosis［J］. JAMA， 2007， 297（11）： 1197-1206.
鲁冬林. 腔内治疗下肢动脉支架内再狭窄的临床应用及疗效分析［D］. 济南：山东大学，2018.
刘颖，张金莲，邓亚羚，等.黄芪多糖提取、分离纯化及其药理作用研究进展［J］. 中华中医药杂志，2021， 36（10）： 6035-6038.
李馨蕊，刘娟，彭成，等. 红花化学成分及药理活性研究进展［J］. 成都中医药大学学报，2021， 44（1）： 102-112.
谭静，林红强，王涵，等. 鸡血藤的药理作用及临床应用研究进展［J］. 中药与临床，2018， 9（5）： 61-65.
封若雨，朱新宇，邢峰丽，等.路路通的药理作用研究概述［J］. 中国中医基础医学杂志，2019， 25（8）： 1175-1178.
蔡卓亚，周自桂，李萍，等. 伸筋草化学成分及药理作用研究进展［J］. 中草药，2015， 46（2）： 297-304.
殷林虹. 积雪草的化学成分分析及药理作用研究进展［J］. 化工管理，2015（17）： 48-49.
0
浏览量
109
下载量
0
CSCD
1
CNKI被引量
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：10154 今日访问量：17